Preclinical studies with toremifene as an antitumor agent Simon P. RobinsonChristopher J. ParkerV. Craig Jordan Symposium lectures and reports Pages: S - S
Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer Peter C. KohlerJohn T. HammDouglass C. Tormey Symposium lectures and reports Pages: S - S
A phase I study of toremifene Takeshi TominagaOsahiko AbeYasuo Nomura Symposium lectures and reports Pages: S - S
Phase II trials with toremifene in advanced breast cancer: A review Ritva Valavaara Symposium lectures and reports Pages: S - S
High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer an ongoing phase II multicenter Finnish-Latvian cooperative study Tenho HietanenDace BaltinaRitva Valavaara Symposium lectures and reports Pages: S - S
Phase III studies of toremifene in metastatic breast cancer Seppo O. Pyrhönen Symposium lectures and reports Pages: S - S
